ClinicalTrials.gg

Program

Tenofovir

Also written as “Tenofovir disoproxil fumarate”, “Tenofovir DF” and “tenofovir”.

Its studies are mostly in Hepatitis B, Chronic · HIV Infections · Hepatitis B · Acquired Immunodeficiency Syndrome · Hepatitis C, led by 12 companies.

Furthest: phase 4, since Mar 23, 200553 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences291 open or runningphase 4since Mar 23, 2005Nov 2, 1999none ahead
GlaxoSmithKline90 open or runningphase 4since May 31, 2002May 31, 2002none ahead
Hoffmann-La Roche30 open or runningphase 3since Mar 16, 2010Aug 19, 2009none ahead
Laboratorio Elea Phoenix20 open or runningphase 4since Oct 10, 2017Oct 19, 2015none ahead
Novartis20 open or runningphase 4since Dec 7, 2006Dec 7, 2006none ahead
Samjin Pharmaceutical20 open or runningphase 4since Feb 25, 2022Feb 25, 2022none ahead
Boryung Pharmaceutical10 open or runningphase 1since Sep 29, 2016Sep 29, 2016none ahead
Daewoong Pharmaceutical10 open or runningphase 4since Mar 27, 2018Mar 27, 2018none ahead
Dong-A ST10 open or runningphase 1since Sep 22, 2015Sep 22, 2015none ahead
new-discovery-llc10 open or runningphase 4since Mar 18, 2018Mar 18, 2018none ahead
Viatris10 open or runningphase 4since Apr 25, 2022Apr 25, 2022none ahead
yung-shin-pharm-ind-co-ltd10 open or runningphase 4since Dec 15, 2020Dec 15, 2020none ahead

Also a collaborator on its studies: c-r-research-inc, almedis and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 38 studies since Nov 2, 1999.

  1. Aug 21, 2012Phase 1 study in Hepatitis B, ChronicGilead Sciences · NCT01671787 · 51 enrolled · United States, Australia, Canada and more
  2. Jul 17, 2014Phase 4 study in Hepatitis B, ChronicGlaxoSmithKline · NCT02195518 · 213 enrolled · China
  3. Aug 21, 2014Phase 4 study in Hepatitis B, ChronicGlaxoSmithKline · NCT02224456 · 197 enrolled · China
  4. Jun 17, 2015Phase 4 study in Hepatitis BGilead Sciences · NCT02479880 · 30 enrolled · Belgium, France, Greece and more
  5. Sep 22, 2015Dong-A ST's first study: phase 1 study in Hepatitis BNew to Dong-A STDong-A ST · NCT02557594 · 36 enrolled · Korea, Republic of
  6. Oct 19, 2015Laboratorio Elea Phoenix's first study: phase 1 study in Acquired Immunodeficiency SyndromeNew to Laboratorio Elea PhoenixLaboratorio Elea Phoenix · NCT02583464 · 24 enrolled · Argentina
  7. Sep 29, 2016Boryung Pharmaceutical's first study: phase 1 study in HepatitisNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT02920931 · 50 enrolled · Korea, Republic of
  8. Aug 21, 2017Phase 4 study in Hepatitis B, ChronicGlaxoSmithKline · NCT03258710 · 75 enrolled · Japan
  9. Oct 10, 2017Phase 4 study in HealthyLaboratorio Elea Phoenix · NCT03309566 · 24 enrolled · Argentina
  10. Mar 18, 2018new-discovery-llc's first study: phase 4 study in Hepatitis BNew to new-discovery-llcnew-discovery-llc · NCT03476083 · 280 enrolled · China
  11. Mar 27, 2018Daewoong Pharmaceutical's first study: phase 4 study in Hepatitis B, ChronicNew to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT03485534 · 189 enrolled · Korea, Republic of
  12. Dec 15, 2020yung-shin-pharm-ind-co-ltd's first study: phase 4 study in Pharmacokinetic of Tenofovir in Healthy SubjectsNew to yung-shin-pharm-ind-co-ltdyung-shin-pharm-ind-co-ltd · NCT04671563 · 28 enrolled · Taiwan
  13. Feb 25, 2022Samjin Pharmaceutical's first studies: 2 phase 4 studies in Hepatitis B, ChronicNew to Samjin PharmaceuticalSamjin Pharmaceutical · NCT05286346, NCT05282407
  14. Apr 25, 2022Viatris's first study: phase 4 study in Hepatitis B, ChronicNew to ViatrisViatris · NCT05355467 · 40 enrolled · Taiwan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 53 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05355467Hepatitis B, Chronic · Taiwan4CompletedViatrisJul 13, 202140
NCT05286346Hepatitis B, Chronic · Korea, Republic of4CompletedSamjin PharmaceuticalAug 10, 2020113
NCT05282407Hepatitis B, Chronic · Korea, Republic of4CompletedSamjin PharmaceuticalApr 17, 2019118
NCT04671563Pharmacokinetic of Tenofovir in Healthy Subjects · Taiwan4Completedyung-shin-pharm-ind-co-ltdMay 9, 202028
NCT03485534Hepatitis B, Chronic · Korea, Republic of4CompletedDaewoong PharmaceuticalNov 4, 2019189
NCT03476083Hepatitis B · China4UNKNOWNnew-discovery-llcMay 2021280
NCT03309566Healthy · Argentina4CompletedLaboratorio Elea PhoenixFeb 28, 201724
NCT03258710Hepatitis B, Chronic · Japan4CompletedGlaxoSmithKlineDec 28, 201875
NCT02920931Hepatitis · Korea, Republic of1CompletedBoryung PharmaceuticalApr 201650
NCT02583464Acquired Immunodeficiency Syndrome · Argentina1CompletedLaboratorio Elea PhoenixOct 201424
NCT02557594Hepatitis B · Korea, Republic of1CompletedDong-A STNov 17, 201536
NCT02479880Hepatitis B · Belgium, France, Greece and more4TerminatedGilead SciencesFeb 28, 201830
NCT02224456Hepatitis B, Chronic · China4CompletedGlaxoSmithKlineDec 4, 2020197
NCT02195518Hepatitis B, Chronic · China4CompletedGlaxoSmithKlineAug 14, 2018213
NCT01671787Hepatitis B, Chronic · United States, Australia, Canada and more1CompletedGilead SciencesApr 201351
NCT01651403Hepatitis B, Chronic · United States, India, Romania and more3Active, not recruitingGilead SciencesAug 7, 201790
NCT01592305Healthy Volunteer · United States1CompletedHoffmann-La RocheJun 201240
NCT01480284Hepatitis B, Chronic · Japan3CompletedGlaxoSmithKlineJan 2013166
NCT01480622Hepatitis B, Chronic · China1CompletedGlaxoSmithKlineDec 30, 201114
NCT01475851Hepatitis B, Chronic · Japan3CompletedGlaxoSmithKlineJun 201334
NCT01300234Hepatitis B · China3CompletedGlaxoSmithKlineOct 17, 2012512
NCT01277601Hepatitis B, Chronic · United States, Australia, Canada and more4CompletedGilead SciencesAug 2014751
NCT01334567Hepatitis B · Taiwan2CompletedGilead SciencesDec 201330
NCT01088659Hepatitis D, Chronic · Turkey3CompletedHoffmann-La RocheDec 29, 201750
NCT00962871Hepatitis B, Chronic · United States, New Zealand, Singapore and more1CompletedHoffmann-La RocheFeb 201230
NCT00737568Hepatitis B · United States, Austria, Bulgaria and more3CompletedGilead SciencesNov 2011280
NCT00736190Hepatitis B, Chronic · United States4CompletedGilead SciencesJul 201090
NCT00734162Hepatitis B · United States, Bulgaria, France and more3CompletedGilead SciencesMar 2011106
NCT00648817HIV Infections · United Kingdom4CompletedGilead SciencesNov 20078
NCT00647946Lipodystrophy · United Kingdom2CompletedGilead SciencesOct 2004100
NCT00643968HIV Infections · France4CompletedGilead SciencesJun 2005140
NCT00651209Hepatitis B, Chronic · Argentina, Brazil, Germany and more4CompletedNovartisDec 2011105
NCT00615745HIV Infections · United Kingdom4CompletedGilead SciencesNov 2010115
NCT00528957HIV Infections · United States, Panama, United Kingdom3CompletedGilead SciencesApr 6, 200997
NCT00409019Hepatitis B, Chronic4WithdrawnNovartisMar 20110
NCT00365612HIV Infections · United States, Puerto Rico4CompletedGilead SciencesOct 2007300
NCT00352053HIV Infections · Brazil, Panama3CompletedGilead SciencesSep 200887
NCT00324688HIV Infections · Germany4CompletedGilead Sciences60
NCT00307489Hepatitis B, Chronic · United States, France, Germany and more2CompletedGilead SciencesJan 2008106
NCT00298363Hepatitis B, Chronic · United States, Canada, France and more2CompletedGilead SciencesApr 2011112
NCT00158821HIV Infections3CompletedGilead SciencesDec 2001180
NCT00112047HIV Infections · United States3CompletedGilead SciencesFeb 2005517
NCT00106379HIV Infections · United States4CompletedGilead Sciences52
NCT00053638HIV Infections · United States3CompletedGlaxoSmithKlineOct 2004345
NCT00038506HIV Infections · United States4CompletedGlaxoSmithKlineAug 2004100
NCT00016588HIV Infections · United States–CompletedGilead Sciences
NCT00011089HIV Infections · United States–UNKNOWNGilead Sciences
NCT00007436HIV Infections · United States3UNKNOWNGilead Sciences
NCT00002453HIV Infections · United States–CompletedGilead Sciences300
NCT00002450HIV Infections · United States, Puerto Rico3CompletedGilead Sciences600
NCT00002415HIV Infections · United States2CompletedGilead Sciences175
NCT00002396HIV Infections · United States1UNKNOWNGilead Sciences60
NCT00002180HIV Infections · United States1CompletedGilead Sciences

How it is read

Names in the registry

  • “Tenofovir disoproxil fumarate”, 13 entries
  • “Tenofovir”, 7 entries
  • “Tenofovir DF”, 6 entries
  • “tenofovir”, 5 entries
  • “TDF”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.